Merrimack Pharmaceuticals

Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDETM (irinotecan liposome injection), was approved by the U.S. FDA on October 22, 2015. With four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, Merrimack is building one of the most robust oncology pipelines in the industry.

Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2000
Size (employees)
294 (est)-30%
Merrimack Pharmaceuticals was founded in 2000 and is headquartered in Cambridge, US

Key People at Merrimack Pharmaceuticals

Robert J. Mulroy

Robert J. Mulroy

President and Chief Executive Officer, Board of Directors
Ulrik B. Nielsen

Ulrik B. Nielsen

Founder
Gary Crocker

Gary Crocker

Chairman
Peter Laivins

Peter Laivins

Team Member
Edward J. Stewart

Edward J. Stewart

Team Member
William A. Sullivan

William A. Sullivan

Team Member

Merrimack Pharmaceuticals Office Locations

Merrimack Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
1 Kendall Square

Merrimack Pharmaceuticals Metrics

Merrimack Pharmaceuticals Financial Metrics

Revenue (2016)

$144.3 m

Revenue growth (2015-16), %

62%

Gross profit

$137.4 m

Gross profit margin (2016), %

95%

Net income (2016)

($153.5 m)

Market capitalization (21-Mar-2017)

$415.2 m

Closing share price (21-Mar-2017)

$3.2

Cash (31-Dec-2016)

$21.5 m
Merrimack Pharmaceuticals's current market capitalization is $415.2 m.
Merrimack Pharmaceuticals's revenue was reported to be $144.3 m in FY, 2016 which is a 61.6% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$47.8 m$102.8 m$89.3 m$144.3 m

Revenue growth, %

115%(13%)62%

Cost of goods sold

$6.9 m

Gross profit

$89.2 m$137.4 m

Gross profit Margin, %

100%95%

Operating expense total

$218.8 m$254.4 m

EBIT

($120.5 m)($66.3 m)($129.6 m)($110.1 m)

EBIT margin, %

(252%)(64%)(145%)(76%)

Interest expense

$19.2 m$43.6 m

Interest income

$99 k$276 k

Net Income

($130.7 m)($83.6 m)($147.8 m)($153.5 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$65.1 m$35.7 m$185.6 m$21.5 m

Accounts Receivable

$5.9 m$3.3 m$6.5 m$17.5 m

Inventories

$5.5 m$4.7 m$5.5 m$3.8 m

Current Assets

$166.6 m$132.1 m$201.4 m$57.4 m

PP&E

$13.4 m$14.5 m$21.9 m$15.8 m

Goodwill

$3.6 m$3.6 m$3.6 m$3.6 m

Total Assets

$192.4 m$158.7 m$234.9 m$81.5 m

Accounts Payable

Current Liabilities

$57.7 m$111.1 m$103.7 m$88.2 m

Additional Paid-in Capital

$527.8 m$552 m$617.1 m$702.4 m

Retained Earnings

($572.2 m)($655.2 m)($802.2 m)($954.8 m)

Total Equity

($43.5 m)($102.1 m)($183.9 m)

Financial Leverage

-4.4 x-1.6 x-1.3 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($130.7 m)($83.6 m)($147.8 m)($153.5 m)

Depreciation and Amortization

$2.6 m$3.2 m$4.3 m$6.2 m

Accounts Receivable

$3.4 m$2.6 m($3.2 m)($11 m)

Inventories

$4 m$827 k($850 k)$1.9 m

Accounts Payable

Cash From Operating Activities

($95.2 m)($34.8 m)$149.9 m($170.2 m)

Purchases of PP&E

($9.9 m)($6 m)($12.8 m)($3.2 m)

Cash From Investing Activities

($27.7 m)($6 m)$75.1 m($3.3 m)

Interest Paid

$3.9 m$9.5 m$10.1 m$23.9 m

Merrimack Pharmaceuticals Market Value History

Merrimack Pharmaceuticals Median Salaries

Source: 20 public H-1B filings from Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Online Presence

Merrimack Pharmaceuticals News

Merrimack Pharmaceuticals Company Life

You may also be interested in